REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Stack Library

Hair Growth Stack

Skin & Hairintermediate

78

synergy

78
Peptides

3

Avg Daily mcg

3,250

Level

intermediate

Added

May 17, 2026

Overview

The Hair Growth Stack combines three regenerative peptides that target different aspects of hair follicle biology to promote hair density, thickness, and growth cycle optimization. GHK-Cu is the primary driver of this stack''s hair-specific effects. The copper-binding tripeptide has been shown to increase hair follicle size, stimulate proliferation of follicular keratinocytes, and extend the anagen (active growth) phase of the hair cycle. Studies demonstrate that GHK-Cu promotes expression of growth factors specific to the dermal papilla cells that control hair follicle activity, including FGF-7, VEGF, and Wnt signaling pathway components. Topical application allows direct delivery to the scalp, though subcutaneous injection provides systemic support for body-wide follicle health. BPC-157 contributes to hair restoration through its angiogenic properties — hair follicles are among the most metabolically active structures in the body and require robust blood supply. In androgenetic alopecia, miniaturization of follicles correlates with reduced perifollicular vascularity. BPC-157''s promotion of new blood vessel formation around follicles restores the nutrient and oxygen delivery needed for full-size hair production. Additionally, its anti-inflammatory effects may help resolve the chronic perifollicular inflammation (micro-inflammation) now recognized as a contributor to pattern hair loss. TB-500 provides systemic tissue remodeling support through its actin-polymerization and cell migration effects. Hair follicle cycling involves extensive tissue remodeling — the follicle partially destructs during catagen, then regenerates from stem cells during the telogen-to-anagen transition. TB-500''s promotion of stem cell migration and tissue repair supports these regenerative processes. The three-peptide combination addresses follicular vascularity (BPC-157), direct follicle stimulation and matrix remodeling (GHK-Cu), and systemic tissue repair capacity (TB-500). Results typically require 3-6 months of consistent use, as hair growth cycles operate on timescales of months rather than weeks.

Dosing Protocol

GHK-Cu

Every day· topical/subcutaneous

500 mcg

per dose

BPC-157

Every day· subcutaneous

250 mcg

per dose

TB-500

2x/week· subcutaneous

2,500 mcg

per dose

Goals & Evidence

Hair growthFollicle stimulationHair densityScalp vascularityAlopecia support
Evidence tier:Animal Studies

Warnings

  • Hair-related applications of BPC-157 and TB-500 are off-label. GHK-Cu topical data is strongest for this indication.

Disclaimer: This stack is community-submitted and for research purposes only. PeptideVault does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.